March 2nd, 2015
This week’s topics include NSAID use in patients receiving antithrombotic therapy after MI, sauna bathing, Eugene Braunwald’s lecture on the war against heart failure, and more.
January 26th, 2015
This week’s topics include dietary sodium content, mortality, and CVD risk in older adults, the ROX CONTROL HTN study, and more.
September 22nd, 2014
This week’s topics include one-year outcomes after thrombus aspiration for MI, the evaluation and treatment of older patients with hypercholesterolemia, and more.
September 8th, 2014
Harsh Golwala presents our latest case: A 25-year-old woman, 32 weeks pregnant, presents with sudden-onset chest pain. How do you proceed?
September 1st, 2014
Until recently, MI patients receiving emergency PCI would only have the culprit artery opened. Complete revascularization of non-infarct-related arteries was performed later. The conventional wisdom was that revascularization of non-infarct-related arteries could be dangerous. That wisdom began to change last year with the PRAMI trial, which found no evidence of harm and a suggestion of benefit in […]
July 17th, 2014
TACT investigator Gervasio Lamas provides perspective on two new TACT papers that appear to have contradictory results.
May 8th, 2014
This week’s topics include darapladib for preventing ischemic events in stable CHD, the DAMASCENE analysis, a review of John Brush’s new book, and more.
February 10th, 2014
This week’s topics include two reports of cobalt-induced heart failure, a comparison of CABG and PCI, and more.
January 23rd, 2014
Two studies published this week offer fresh evidence that the time and place of a myocardial infarction (MI) make a big difference. 1. MI patients in the United Kingdom are more likely to die than MI patients in Sweden, according to a study published in the Lancet. Researchers in Sweden and the U.K. analyzed data from almost 120,000 Swedish patients […]
January 13th, 2014
This week’s topics include the risk for MI and ischemic heart disease among overweight and obese people with and without metabolic syndrome, and the lower risk for CV events in postmenopausal women taking estradiol compared with conjugated equine estrogens.